SecBot SecBot
8-K ·Filed Aug 4, 2026

PVLA

PALVELLA THERAPEUTICS, INC.
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago SEC0001193125-26-331556
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The EPS miss is noise for a pre-revenue biotech; the stock will trade on NDA submission progress and the potential for a first-in-disease approval. Monitor for completion of the rolling NDA in H2 2026 and any FDA feedback or advisory committee announcement, which would be the next major catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$151.99
T+0 close · Aug 4, 2026 · via day close
Latest settled
−12.55%
T+60 · $132.91
Vs SPY
−12.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $151.99entry
  2. T+1 · 3mo ago +1.92%α +2.12% · $154.91
  3. T+5 · 3mo ago +1.52%α +1.62% · $154.30
  4. T+20 · 3mo ago −0.95%α +0.29% · $150.55
  5. T+60 · 20d ago −12.55%α −12.93% · $132.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics reported Q2 2026 results with a net loss of $1.52 per share, missing the consensus estimate of $-1.15 by 32%. The company is a pre-revenue clinical-stage biotech, so the EPS miss is a mechanical artifact of increased R&D spending and share dilution from the February 2026 equity raise, not a business deterioration signal. The key catalyst is the ongoing rolling NDA submission for QTORIN rapamycin in microcystic lymphatic malformations, which remains on track for completion in H2 2026, with a potential U.S. launch in H1 2027. The company has a strong cash position of $250.6M, funding operations and launch preparations through 2027.

Key Financial Metrics

EPS
−$1.52
est −$1.15 · -32.2%
Rating
miss

Key Facts

  • Net loss of $21.9M ($1.52/share) for Q2 2026, compared to net loss of $9.5M ($0.86/share) in Q2 2025.
  • EPS of $-1.52 missed the consensus estimate of $-1.15 by 32%.
  • Cash, cash equivalents, and short-term investments were $250.6M as of June 30, 2026.
  • First module of the rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations submitted to FDA; completion on track for H2 2026.
  • Company preparing for a potential standalone U.S. commercial launch in H1 2027, if approved.
  • Phase 3 trial for cutaneous venous malformations on track for Q4 2026 initiation.
  • Anticipated full-year 2026 cash expenses of $85 to $95 million.

Financial Impact

Net loss increased to $21.9M in Q2 2026 from $9.5M in Q2 2025, driven by higher R&D and G&A expenses as the company scales for NDA submission and commercial launch.

net losscash positionoperating expenses

Risk Factors

  • Regulatory risk: FDA may not accept the NDA or may require additional clinical data, delaying or preventing approval.
  • Commercial risk: If approved, the company must successfully launch a novel therapy in a rare disease with no prior approved treatments, facing challenges in market access, physician education, and patient uptake.
  • Dilution risk: The company is pre-revenue and will likely need to raise additional capital to fund operations beyond its current cash runway, potentially diluting existing shareholders.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-331556
Document: pvla-20260804.htm0001193125-26-331556
Document: pvla-ex99_2.htm0001193125-26-331556
Document: 0001193125-26-331556-index-headers.html0001193125-26-331556
Document: 0001193125-26-331556-index.html0001193125-26-331556
Document: 0001193125-26-331556.txt0001193125-26-331556
8-K Data (Synthetic)0001193125-26-331556

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026